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ABSTRACT: Type 1 diabetes (T1D) results from the destruction of pancreatic b-cells by the immune system, and CD8+
Tlymphocytesarecritical actors in thisautoimmuneresponse.Pancreatic isletsaresurroundedbyameshofnervouscells,
theperi-insular Schwann cells,which are also targetedby autoreactiveT lymphocytes andexpress specific antigens, such
as the neurotrophic factor S100-b. Previous work has shown increased proliferative responses to whole S100-b in both
humanT1Dpatients and the nonobese diabetic (NOD)mousemodel.We describe for the first time naturally processed
and presented epitopes (NPPEs) presented by class I human leukocyte antigen–A*02:01 (A2.1) molecules derived from
S100-b. These NPPEs triggered IFN-g responses more frequently in both newly diagnosed and long-term T1D patients
comparedwithhealthydonors.Furthermore, thesameNPPEsarerecognizedduring theautoimmuneresponse leading to
diabetes in A2.1-transgenic NOD mice as early as 4 wk of age. Interestingly, when these NPPEs are used to prevent
diabetes in this animalmodel, an acceleration of the disease is observed togetherwith an exacerbation in insulitis and an
increase inS100-b–specific cytotoxicity invaccinatedanimals.Whether these canbeused indiabetespreventionneeds to
be carefully evaluated in animalmodels beforeuse in future clinical assays.—Calviño-Sampedro,C.,Gomez-Tourino, I.,
Cordero,O. J., Reche, P. A., Gómez-Perosanz,M., Sánchez-Trincado, J. L., Rodrı́guez,M. Á., Sueiro, A.M., Viñuela, J. E.,
Calviño, R. V.Naturally presentedHLA class I–restricted epitopes from the neurotrophic factor S100-b are targets of the
autoimmune response in type 1 diabetes. FASEB J. 33, 000–000 (2019). www.fasebj.org
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Schwann cells
One of the hallmarks of type 1 diabetes (T1D) in both hu-
man patients and nonobese diabetic (NOD) mice is the
destruction of the insulin-producing b-cells in the pan-
creatic islets. The autoimmune origin of this attack comes
from several lines of evidence, including the detection of
autoantibodies years before clinical disease onset (1) and
the detection of T lymphocytes specific for the very same
antigens (2–5).
During this process, pancreatic islets are infiltrated by
different immune cell types, including CD4+ and CD8+
T lymphocytes (4, 6, 7). However, CD8+ lymphocytes are
critical for diabetes development. First, neither insulitis
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nor diabetes develops in NOD mice lacking major histo-
compatibility complex (MHC) class Imolecules andCD8+
T cells (8). Second, in human T1D, there is a linkage
to susceptibility to particular human leukocyte antigen
(HLA) class I molecules, such as A*2401 and A*0201, and
also toprotection, suchasA*01andA*1101 (9, 10). Finally,
in human T1D patients, CD8+ T lymphocytes are the
predominant cell subset seen in insulitic lesions linked to a
hyperexpression of HLA class I molecules (2, 11, 12).
Several targets of this inflammatory responsehavebeen
identified, among which preproinsulin, glutamic acid
decarboxylase 65 (GAD65), and insulinoma-associated
protein 2 (IA-2)–b have been repeatedly cited in the liter-
ature (13).Recent results inboth theNODmiceandhuman
T1D patients have led to the identification of other im-
portant targets for those autoreactive T lymphocytes,
such as zinc transporter 8 or islet-specific glucose-6-
phosphatase–related protein (14, 15).
However, during diabetes development, peri-insular
Schwann (pSC) cells are also targeted by autoreactive
lymphocytes (16). pSC cells organize a network, forming a
mesh surrounding the islets (16, 17). In NOD mice, lym-
phocytic infiltration leads to the breakdown of the pSC
network and the development of insulitis (17, 18). pSC cells
express specific antigens, such as glial fibrillary acidic pro-
tein (GFAP) and the neurothrophic factor S100-b. Those
antigens havebeen shown tobe targetedby autoantibodies
(19, 20) and T lymphocyte responses (16, 21–25). Lym-
phocyte proliferation against GFAP and S100-b antigens
has been demonstrated in NOD mice and human T1D
patients (16, 22). In the case of GFAP, I-Ag7 and Kd peptide
epitopes have been described in NOD mice (21), and
HLA-A2.1–restrictedpeptide epitopeshavebeendescribed
in humans (24). Recently, naturally processed and pre-
sented epitopes (NPPEs) derived fromS100-b, restrictedby
the HLA-DRB1*04:01 (HLA-DR4) class II molecule, and
targetedby the autoimmune response in T1Dpatients have
been identified (23). InNODmice,peptideepitopesderived
from S100-b and recognized by CD4+ T lymphocytes have
also been described (25); interestingly, dominant S100-b–
derived epitopes in NODmice lie within the same regions
as those targeted by human T responses.
Immunotherapies employing either whole GFAP or
S100-bprotectNODmice fromdiabetesdevelopment (16).
Moreover, immunotherapy with class II I-Ag7– and class I
Kd–restrictedpeptideepitopesderived fromGFAPprotect
NOD mice from diabetes development (21). These data
indicate that immunotherapy with pSC-derived antigens
could prevent the development of clinical symptoms.
Despite these results, no S100-b peptide epitopes tar-
geted by CD8+ cytotoxic T lymphocytes (CTLs) in T1D
patients have been identified, nor has their potential ef-
fectiveness in preventing diabetes development been re-
ported. In the present study, we have identified several
NPPEs derived from S100-b and presented by the class I
HLA molecule A*02:01 (A2.1). We hypothesized that re-
sponses against these peptide epitopesmight be present in
both human T1D patients andA2.1-transgenic NODmice.
Our results support this hypothesis: higher responses
against some S100-b–derivedNPPEs can be detectedmore
frequently in both newly diagnosed (ND) and long-term
T1D patients. Furthermore, T1D patients respond more
frequently and with higher intensity to more than 1 epi-
tope. Similar responses can be detected in A2.1-transgenic
NOD mice as early as 4–5 wk of age. When these peptide
epitopes were used for immunotherapy, an apparent ac-
celeration of disease development was observed together
with a worsening in the insulitic lesions and increased cy-
totoxicity against S100-b–positive targets by CTLs. Our
results highlight the need for careful evaluation of different
administration routes and dosage protocols using this an-
tigen to ameliorate the autoimmune response in T1D.
MATERIALS AND METHODS
Cloning of S100-b and generation of an S100-
b–expressing surrogate antigen-presenting cell
S100-b cDNA(GenBankaccessionno. BC001766.1)was obtained
from SourceBioscience (Nottingham, United Kingdom) and
subcloned into the BamHI site of the pcDNA3.1/Zeo(+) vector
(Thermo Fisher Scientific, Waltham, MA, USA).
A surrogate antigen-presenting cell was generated by trans-
fection of an HLA-A2.1–expressing K562 cell line (K562/A2.1)
with S100-b/pcDNA3.1-Zeo using Lipofectamine (Thermo
Fisher Scientific) following the manufacturer’s instructions.
Clones expressing high levels of S100-b were selected using
Geneticin and Zeocin (Thermo Fisher Scientific).
Expression of both A2.1 and S100-b was verified by flow
cytometry and immunofluorescence. For flow cytometry, cells
were surface stained with an anti-human HLA-A2.1–FITCmAb
(BB7.2 clone) (BD Biosciences, San Jose, CA). Afterwashing, cells
were fixed and permeabilized (Cytofix/Cytoperm; BD Biosci-
ences) andstained intracellularlywith amouseanti–S100-bmAb
(Abcam, Cambridge, MA, USA) followed by an anti-mouse IgG
phycoerythrin-labeled goat pAb (Abcam) and analyzed using a
BD FACScalibur flow cytometer (BD Biosciences).
For immunofluorescence analysis, cells were fixed onto poly-L-
Lysine–coated coverslips; stained with either the BB7.2-FITC
antibody (surface) or, after fixation/permeabilization, the S100-b–
FITC antibody (Abcam) (intracellular) andDAPI; and imaged in an
Olympus BX51 fluorescence microscope (Olympus, Tokyo, Japan).
Identification of HLA-A2.1–restricted NPPEs derived
from S100-b
Peptides bound to A2.1 in the cell surface of either K562/A2.1 or
K562/A2.1–S100-b were eluted by a brief incubation in acid cit-
ratebuffer (pH3.3) andsequentiallyenrichedusinga3kDacutoff
AmiconUltra Filter (MilliporeSigma, Burlington,MA,USA) and
a Discovery DSC-18 trifunctional C18 silica resin column (Milli-
poreSigma). Peptide fractionation was done using a 150 mm 3
2.1 mm BioBasic 18 column (Thermo Fisher Scientific), and
peptide-containing fractions were stored at280°C until analysis
by mass spectrometry (MS).
MS was carried out in the Spectrometry Service [Instituto de
Investigaciones Sanitarias (IDIS), Santiago de Compostela] on a
matrix-assisted laser desorption/ionisation–time of flight mass
spectrometry (MALDI-TOF) MS Analyzer (Thermo Fisher Sci-
entific). The analysis was carried out with the 4000 Series Ex-
plorer software v.3.5 (Thermo Fisher Scientific) andMascot v.2.1
(Matrix Science, Boston, MA, USA) to search against a National
Center for Biotechnology Information nonredundant (NCBInr)
protein database or in an S100-b–specific database. Unique m/z
values were identified using Findpept (http://web.expasy.org/
findpept/) to select those that could be derived from S100-b. Po-
tential unique peptide epitopes of 8–10 aa long were chosen.
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In vitro proteasome digestion and in silico
proteasomal cleavage analysis of purified
human S100-b
Purified human S100-b (23) was incubated with purified 20S
proteasome (Enzo Life Sciences, Farmingdale, NY, USA) (molar
ratio 250:1) in digestion buffer [30mMTris-HCl (pH 8.0), 10mM
NaCl, 2 mMMgCl2, 1 mM DTT, 0.01% sodium dodecyl sulfate)
for 16 h at 37°C. As a control, the same digestion was set up
with either no proteasome or with acetic acid (1%)–inactivated
proteasome. Generated peptideswere purified and concentrated
using a cationic resin (ZipTip with strong cation exchange; Mil-
liporeSigma) followingthemanufacturer’s instructions.Retained
peptides were eluted from the resin and analyzed by MS.
The S100-b humanprotein sequencewas analyzed in silico for
potential proteasome and immunoproteasome cleavage sites
using several published algorithms (26, 27).
Peptides
S100-b–derived NPPEs S10010–18 (ALIDVFHQY) and S10020–28
(GREGDKHKL)were synthesized byChinaPeptide (Hangzhou,
China) to .90% purity. A stock of 100 mg/ml in DMSO was
prepared for each peptide and stored at220°C until use.
HLA stabilization assay
Binding of the S100-b NPPE candidates was examined by a
conventional HLA stabilization assay as previously described
(28). Briefly, T2 cells were washed twice with serum-free AIMV
medium (Thermo Fisher Scientific) and incubated in medium
containing b2-microglobulin (MilliporeSigma) and each of the
test peptides at various concentrations (100–0.78 mM). Surface
A2.1 expression was determined using the BB7.2 antibody in a
FACSCalibur flow cytometer.
Human donors
In total, 35 subjects were studied: 18 nondiabetic healthy donors
(HDs)without family history of disease and 7ND (,1 yr) and 10
long-standing (LS) (.1 yr) T1D patients. Blood was drawnwith
the informed consent of all subjects and appropriate permission
was obtained from the Institutional Ethics Committee (Comité
Ético de Investigación Clı́nica de Galicia, CEIC). T1D patients
were enrolled from those attending the diabetic clinic at the En-
docrinology Service (Hospital de Conxo, Santiago de Compos-
tela, Spain). Healthy nondiabetic donors were recruited from
laboratory and hospital staff during the same period. HLA-DR4
and HLA-A2.1 positivity was determined by PCR as previously
described by Bunce (29). GAD65 and IA-2 autoantibodies were
determined by ELISA (Palex Medical, Barcelona, Spain).
Mice
Transgenic NOD.B6-Tg(HLA-A2.1)1Enge/DvsJ mice were pur-
chased fromThe JacksonLaboratory (BarHarbor,ME,USA) and
maintained in the specific-pathogen–free facilities at the Molec-
ular Medicine and Chronic Diseases Research Centre (Santiago
de Compostela). Glucosuria was determined weekly from 8 wk
of age onwardusingMedi-TestGlucose Strips (Macherey-Nagel,
Düren, Germany). Diabetes was diagnosed when glucose levels
were $500 mg/dl (27.8 mM) in 2 consecutive measures. All ex-
perimental procedures were approved by the corresponding
ethics committee. Splenocytes were stained with the BB7.2 anti-
body to confirm A2.1 expression.
To obtain single-cell suspensions, spleens were passed
through a 70-mm pore size filter (Corning cell strainer; Corning,
Corning, NY, USA) and centrifuged over a Ficoll gradient.
S100-b NPPE immunotherapy
Animmunotherapyprotocolwasperformedaspreviouslydescribed
by Han et al. (30). Briefly, female mice were immunized intraperito-
neally with a 1:1 mixture of S10010–18 and S10020–28 in saline. Im-
munizations started at 4wk of age andwere performed every 2wk
until 8 wk of age or 3 wk thereafter. Mice were followed until they
becamediabeticor reached30wkofage.High (100mg/peptide)and
low (10 mg/peptide) peptide doses were evaluated. As a control,
female mice were inoculated with saline containing DMSO (0.2%).
Insulitis and immunohistochemistry
Bouin-fixed pancreases were included in paraffin, and 3 parallel
series with 16 mm thick sections were obtained. Sections were
stainedwith hematoxylin-eosin, and between 30 and50 islets per
mouse were scored in a blinded fashion. Quantification of insu-
litiswith agewas done using 5–6 animals per age group. Insulitis
score in treated animals was determined after diabetes diagnosis
or at 30 wk of age. Each islet was scored according to the scale
indicated in the supplemental data.
For immunohistochemistry, pancreases were fixed in 4% para-
formaldehyde. Sections were pretreatedwith Proteinase K (10mg/
ml) for 5 min at room temperature. Sections were rinsed in 0.05 M
Tris-buffered saline (TBS) (pH 7.4) for 5 min and treated with 10%
H2O2 inTBS(30min, roomtemperature).After rinsing in0.05MTBS
(pH 7.4) for 5 min, sections were incubated overnight at room
temperature with an anti-GFAP mouse mAb (clone 2A5; Abcam).
Sectionswererinsed3times inTBS(10mineach)andincubatedwith
ananti-mousehorseradishperoxidase–coupledsecondaryantibody
(1 h, room temperature). Sectionswere developedwith 0.25mg/ml
diaminobenzidine tetrahydrochloride (MilliporeSigma) in TBS (pH
7.4) and 0.00075% H2O2 and counterstained with hematoxylin-
eosin.AlldilutionsweremadewithTBScontaining15%normalgoat
serum(MilliporeSigma)and0.2%TritonX-100 (MilliporeSigma).All
incubations were carried out in a humid chamber. Finally, the sec-
tions were dehydrated andmounted.
Enzyme-linked immunospot assays
IFN-g enzyme-linked immunospot (ELISPOT)assays (U-CyTech
Biosciences, Utrecht, TheNetherlands) were used to detect S100-
b–specific responses according to the manufacturer’s instruc-
tions.Mouse splenocytes were used in all assays, and an indirect
ELISPOT assay was performed with a 6-h prestimulation step.
When human responses were analyzed, a direct ELISPOT assay
was performed (3 3 105 peripheral blood mononuclear cells
(PBMCs)/well in triplicates per antigen) with a 24-h stimulation
period with the corresponding peptide/antigen.
Peptides were added to a final concentration of 10 mM. Both
culture medium alone and DMSO (0.5%) were used as negative
controls. CEF Peptide Pool (Mabtech AB, Nacka, Sweden) or
concanavalin A (25 ng/ml) were used as positive controls in
human and mouse ELISPOTs, respectively.
Data are expressed as a stimulation index (SI) (SI = total spots
with antigen/total spots with DMSO). In human ELISPOTs, a
response was considered positive when the SI was above the
threshold determined using receiver-operating characteristic
(ROC) curves. In mouse ELISPOTs, a response was considered
positive when the SI was.2.
Cytotoxicity assays
Lysis of peptide-loaded targetswas done as previously indicated
by Neri et al. (31). Briefly, splenocytes from young nondiabetic
female mice were used as targets, whereas splenocytes from ei-
ther saline- (n = 5) or S100-b– (n = 13) vaccinatedmicewere used
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as effectors. Target cells were incubated 2 h with S100-b NPPEs
(both at 10 nM) or DMSO and stained with calcein (15 mM)
(MilliporeSigma). Cells were washed, and 1 3 104 cells were
plated in U-bottom, 96-well plates. Effector cells were added in
quadruplicates at different effector:target ratios (1:1 to 40:1).
Maximum lysis was obtained by adding 2% Triton X-100 to
target cells, and spontaneous lysis was obtained by adding cul-
ture medium to target cells. After 4 h of incubation, fluorescence
(530 nM) in culture mediumwas determined in a Synergy H1M
plate reader (BioTek Instruments, Winooski, VT, USA). The
percentage of cytotoxicity was calculated as (MFsample 2
MFspontaneous)/(MFmaximum 2MFspontaneous)3 100, where MF is
mean fluorescence.
Statistical analysis
Differences in the percentage of highly infiltrated islets and the
frequency of positive responses among different groups were
analyzed using Fisher’s exact test. Comparison of median re-
sponses in ELISPOT assays between groupswas done using the
Mann-Whitney U test or the Kruskal-Wallis test for multiple
comparisons. Survival was analyzed using the log-rankMantel-
Cox test. A value of P # 0.05 was considered significant. All
statistical analysis was done using SPSS v.24 (IBM SPSS, Chi-
cago, IL, USA) and Prism (GraphPad, La Jolla, CA, USA).
RESULTS
Generation of surrogate antigen-presenting
cells for the identification of A2.1-restricted
S100-b–derived NPPEs
Several clones were obtained from the original K562-
A2.1/S100-b cell line, and 4 were selected based on their
expression of both A2.1 and S100-b (Supplemental Fig.
S1A, B), confirming the generation of a surrogate antigen-
presenting cell.
No significant differences were noted between chro-
matograms from K562/A2.1 and K562/A2.1–S100-b–
eluted peptides (Supplemental Fig. S1C). In total, 44
peptide-containing fractions were analyzed by MS, iden-
tifying 7298 and 7027 m/z masses from K562/A2.1 and
K562/A2.1–S100-b cells, respectively. Up to 3403 m/z
could be derived from S100-b, allowing a 1 Da error, with
just 2035m/z remainingwhenonlypeptidesbetween8and
11 aa long were kept. These m/z masses were compared
with the equivalent fraction derived fromK562/A2.1 cells
as well as the immediately preceding and posterior frac-
tions looking for unique masses. This analysis led to the
identification of 4 unique candidate masses (Table 1).
Most predictions for each experimental m/z correspond
either to overlappingpeptides or peptides lyingwithin the
same short region of S100-b (Table 1).
Proteasome cleavage and A2.1 binding
affinity of candidate S100-b NPPEs
From all the sequences shown in Table 1, potential
proteasome cleavage sites are predicted by several algo-
rithms for 5peptide sequences (10–18ALIDVFHQY; 20–28
GREGDKHKL; 38–45 NNELSHFL; 54–61 VDKVMETL;
67–75 GECFQEFM). We next determined the in vitro
proteasome cleavage pattern of S100-b by digestion with
purified 20S proteasome. The use of active proteasome
generates multiple unique fragments (Fig. 1A, B, bottom
panels), which were not present when S100-b was in-
cubated alone (Fig. 1A, B, top panels) or with inactivated
proteasome (Fig. 1A,B,middlepanels).Uniquem/zpresent
in samples of S100-b incubated with active proteasome
were analyzed by tandem MS and Mascot, and 9 of them
were identified as being derived from S100-b (Fig. 1A, B,
bottompanels, arrows), withmany of these corresponding
to its amino-terminal end (Fig. 1C). Comparison of
proteasome-generated peptides with A2.1-eluted peptide
MS data (Table 1) indicates that the carboxy-terminal
end of peptides S10010–18 (ALIDVFHQY) and S10020–28
TABLE 1. NPPEs derived from S100-b and presented by the A2.1 molecule
Experimental m/z Theoretical m/z ΔDa Sequence Position
935.26 934.491 20.934 VDKVMTEL 54–61
935.359 20.067 ETLDNDGDG 59–67
935.359 20.067 TLDNDGDGE 60–68
936.398 0.971 VMETLDND 57–64
974.290 973.474 20.816 INNELSHF 37–44
973.474 20.816 NNELSHFL 38–45
973.520 20.769 EIKEQEVV 47–54
973.640 20.649 KLKKSELK 27–34
974.356 0.065 GECDFQEF 67–74
974.515 0.225 KEQEWDK 49–56
974.588 0.298 LKKSELKE 28–35
974.588 0.298 KKSELKEL 29–36
1039.565 1039.480 20.084 QYSGREGDK 17–25
1039.564 0.000 GREGDKHKL 20–28
1105.506 1105.396 20.109 GECDFQEFM 67–75
1105.568 0.061 ALIDVFHQY 10–18
ΔDa, difference between experimental and theoretical m/z (in Da); Experimental m/z, unique m/z
present only in the peptide mix derived from K562/A2.1–S100-b cells; Position, amino acid position in
the S100-b protein of the predicted peptide; Sequence, amino acid sequence of the predicted peptide;
Theoretical m/z, m/z predicted by Findpept.
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(GREGDKHKL) is generated by the proteasome, making
these sequences potential HLA class I–restricted epitopes.
MS data and proteasome cleavagewere the 2main criteria
to select theNPPEs to be evaluated in the ELISPOT assays.
Of the 5 peptides with the potential proteasome cleav-
age sites indicated above, only peptide S10010–18
(ALIDVFNQY) demonstrated someweakbinding affinity
for A2.1, whereas for the other 4 S100-b peptides, no
binding affinity could be demonstrated (Supplemental
Fig. S2A). Interestingly, several algorithms (32–35) indi-
cate that S10010–18 is one of the peptides with the highest
binding affinity for A2.1 from all of the potential 9-mer
peptides derived from S100-b (Supplemental Fig. S2B). In
fact, when combining predictions for processing by the
proteasome, transporter associated with antigen pro-
cessing binding, andA2.1 binding affinity (36), S10010–18
is once again the peptide showing the highest combined
prediction score, followed by S10067–75 and S10020–28
(Supplemental Fig. S2B). All of these data combined
suggest that peptide epitopes S10010–18 (ALIDVFHQY)
and S10020–28 (GREGDKHKL) could constitute potential
candidates to be recognized by autoreactive CD8+ T
lymphocytes in T1D patients.
T1D patients show specific T-cell responses
against A2.1-restricted S100-b–derived NPPEs
We investigated whether lymphocyte responses against
S10010–18 and S10020–28 could be detected in T1D patients
by IFN-g ELISPOT (see Table 2 for demographic data).
ROC analysis gives an optimal SI cutoff of 1.85 and
1.75 for S10010–18 and S10020–28, respectively (Fig. 2A);
therefore, an SI $2 was chosen to classify a response as
positive.
Figure 1. MS analysis of in vitro proteasome digestion of purified S100-b. A, B) Spectra corresponding to m/z range of 917–1564
(A) and 1556–3145 (B) are shown. Data for S100-b incubated with no proteasome (top panels), inactive proteasome (middle
panels), or active proteasome (bottom panels) are shown. Unique m/z present only in samples of S100-b incubated with active
proteasome were subsequently identified by tandem MS and analyzed by Mascot (arrows). C) Sequences of the 9 most intense
fragments generated by in vitro digestion of S100-b with purified 20S proteasome are aligned with the amino acid sequence of the
antigen. The m/z for each fragment is shown on the left. The carboxy-terminal amino acid is underlined. The sequences of
potential peptide epitopes eluted from A2.1 are shown at the bottom (carboxy-terminal amino acid is underlined only if the
fragment has been generated by the proteasome and identified by MS). The carboxy-terminal ends of peptides S10010–18
(ALIDVFHQY) and S10020–28 (GREGDKHKL) are generated by the proteasome, making them potential class I–restricted
peptide epitopes.
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Clear responses against at least 1 of the 2 S100-b pep-
tides could be detected (Fig. 2B), and these responseswere
significantlymore frequent amongT1Dpatients thanHDs
for both S100-b peptide epitopes [S10010–18: 64.7% T1D
(11/17) vs. 11.1% HD (2/18). P = 0.0016; S10020–28: 70.6%
T1D (12/17) vs. 16.7% HD (3/18). P = 0.002. Two-tailed
Fisher’s exact test]. Positive responses to S10010–18 couldbe
detected in both HLA-A2.1–positive (n = 6; Fig. 2C, red
squares) and HLA-A2.1–negative (n = 5; Fig. 2C, black
squares) T1Dpatients. A similar result is seen for S10020–28
in HLA-A2.1–positive (n = 7; Fig. 2D, red squares) and
HLA-A2.1–negative (n = 6; Fig. 2D, black squares) T1D
patients. Considering only HLA-A2.1–positive subjects,
responses in A2.1+ T1D patients are still significantly
higher comparedwithHDA2.1+subjects forS10020–28 (P=
0.04; 2-tailed Fisher’s exact test) but not for S10010–18 (P =
0.30; 2-tailed Fisher’s exact test).
The magnitude of the responses (median SIs) is also
higher among T1D patients [S10010–18: 4.8 (T1D) vs. 1.0
(HD). P = 0.004. S10020–28: 4.1 (T1D) vs. 0.9 (HD). P =
0.0006. Mann-Whitney U test] (Fig. 2C, D). Considering
onlyHLA-A2.1–positive subjects, responses inA2.1+ T1D
patients are still significantly higher compared with HD
A2.1+ subjects for S10020–28 (P = 0.02; Mann-Whitney U
test) and almost significant for S10010–18 (P = 0.09; Mann-
Whitney U test).
Wenextdecided to compare the responsesbetweenND
andLST1Dpatients. In the case of S10010–18, the frequency
of positive responses among ND (4/7; 57.1%) and LS (8/
10; 80.8%) T1D patients was higher compared with that
seen inHDs (2/10; 20.0%), reaching statistical significance
only for LS T1D patients (P = 0.002; 2-tailed Fisher’s exact
test) (Fig. 2E). In the case of S10020–28, frequency of positive
responses among ND (6/7; 85.7%) and LS T1D patients
(6/10; 60.0%)wasagainhigher comparedwith that seen in
HD (2/10; 20%), reaching statistical significance only for
ND T1D patients (P = 0.015; 2-tailed Fisher’s exact test)
(Fig. 2F).
Furthermore, the magnitude of the responses (median
SIs) against S10010–18 were significantly higher in LS T1D
patients (13.7) vs. HD (1.0) (Fig. 2E) (P = 0.0024; Kruskal-
Wallis, Dunn’s post hoc test). In the case of S10020–28, me-
dian responses in ND (4.1) and LS (3.6) T1D patients were
significantly higher compared with HD (0.9) (Fig. 2F) (P =
0.01 and P = 0.001, respectively; Kruskal-Wallis, Dunn’s
post hoc test).
Interestingly, dual positivity (i.e., response to both
peptides) is more frequently detected in T1D patients (9/
17; 52.9%) comparedwithHDs (1/18; 5.5%) (P= 0.0027; 2-
tailed Fisher’s exact test) (Fig. 2G).
In summary, all these data indicate that proin-
flammatory lymphocyte responses against the 2 novel
S100-bNPPEs aremore frequent in T1Dpatients, bothND
and LS.
Immune responses against S100-b–derived
NPPEs in the A2.1-transgenic NOD mice
We examined whether similar responses against the
S10010–18 and S10020–28 peptide epitopes could be detected
in the A2.1-transgenic NODmouse preclinical model (37).
Diabetes development kinetics and insulitis in both males
and females in our colony are shown in Supplemental Fig.
S3.
Positive responses by splenocytes against S10010–18 and
S10020–28 can be detected in male [8/22 (36.4%) and 8/22
(36.4%), respectively] (Fig. 3A) and female mice [19/31
(61.3%) and 15/31 (48.4%), respectively] (Fig. 3A). There
are no statistical differences in the percentage of responses
between male and female mice (P = 0.09, P = 0.41; 2-tailed
Fisher’s exact test). However, the magnitude of the re-
sponses (medianSIs) is significantlyhigheramong females
(2.6) when compared with males (1.5) for S10010–18 (P =
0.035; Mann-Whitney U test) (Fig. 3A).
When those responseswere examined according to age
in female mice, responses to both S100-b–derived NPPEs
can be detected as early as 4–5 wk of age (Fig. 3B, C).
These data confirm that S100-b is a target of the auto-
immune response in T1D and that epitopes S10010–18 and
S10020–28 are targeted by T lymphocytes.
Immunotherapy of A2.1-transgenic NOD mice
with S100-b–derived peptides
Wenext evaluated the capacity of these NPPEs to prevent
disease development by periodic immunization of young
female mice. No significant reduction in disease develop-
ment frequency is seen compared with saline-inoculated
mice (Fig. 4A) (100% vs. 84.6%; P = 1.0; 2-tailed Fisher’s
exact test). In fact, S100-b vaccination seems to slightly
accelerate T1D development, although this kinetic does
TABLE 2. HD and T1D patient demographics
Variable HD (n = 19) ND (n = 7) LS (n = 11)
Age [mean 6 SD (yr)] 21 6 1.1 34.6 6 11.8 43.4 6 15.5
Sex (M/F) 5/14 3/4 5/6
Time since diagnosis [mean 6 SD (mo)] N/A 2.6 6 1.2 53.1 6 75.2
Time since diagnosis [range (mo)] N/A 1.0–4.5 10–267
GADA positive (%) N/A 71.4 72.7
IA-2A positive (%) N/A 42.9 36.4
HLA-DR4 positive (%) 15.8 0 50
HLA-A2.1 positive (%) 31.6 40 58.4
F, female; IA-2A, islet antigen 2 autoantibodies; GADA, GAD65 autoantibodies; M, male; N/A, not
applicable.
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not reach statistical significance (Fig. 4A) (P = 0.290; log-
rank, Mantel-Cox). However, vaccination does have an
effect on the cellular autoimmune response, as the number
of highly infiltrated islets is significantly higher in S100-b–
vaccinated animals (Fig. 4B) (P = 0.0054; Fisher’s exact test).
Moreover, numerous GFAP-immunoreactive cells are ob-
served around the islets of youngnondiabetic control female
mice (Supplemental Fig. S4A–D) compared with diabetic
S100-b–immunized female mice, in which these cells are
scarce and show a faint GFAP immunoreactivity (Supple-
mental Fig. S4E–H, see arrows in panels F and H). Some
immunoreactive intra-islet cellsarealsoseen in thepancreatic
isletsofcontrolanimals (SupplementalFig.S4,arrowheads in
panelsBandD),whichareabsent in the immunizedanimals.
These results show a decrease in the number of pSC cells in
the S100-b–immunized animals compared with young
nondiabetic insulitis-free female mice.
Despite this increase in islet infiltration severity, posi-
tive responses against S10010–18 (70%, 7/10) (Fig. 4C, S100-
b) or S10020–28 (50%, 5/10) (Fig. 4D, S100-b) are not
significantlyhigher than that observed innonmanipulated
animals (S10010–18: 53.1%, 17/32; S10020–28: 48.4%, 15/31)
(Fig. 4C, D, spontaneous) or inoculated with saline
(S10010–18: 66.7%, 8/12; S10020–28: 66.7%, 8/12) (Fig. 4C,D,
saline) (P . 0.05; Fisher’s exact test). Moreover, vaccina-
tion with S100-b–derived NPPEs does not significantly
modify the intensity of the response measured as the me-
dian SI (P = 0.4; Kruskal-Wallis test).
To addresswhether theunexpected findingof high islet
infiltration in S100-b–treated animals was due to the
Figure 2. IFN-g ELISPOT analysis of responses against S10010–18 and S10020–28 peptide epitopes. A) ROC curves were performed
to discriminate optimal cutoff values between responders and nonresponders, giving an SI cutoff of 1.85 and 1.75 for S10010–18
and S10020–28, respectively. An SI $2 was used as a cutoff. B) A representative response from a T1D patient is shown (in
parentheses, spot mean number 6 SD of triplicate wells) for S10010–18 and S10020–28. A peptide mixture containing known
peptide epitopes derived from viral proteins (CEF) was included as a positive control. Spontaneous responses were determined
by PBMC culture in medium alone (culture medium) or medium containing 0.5% DMSO. C–F) IFN-g secretion in response to
S10010–18 (C, E) and S10020–28 (D, F) by PBMCs from HDs, all T1D patients (T1D), ND T1D patients (T1D-ND), and LS T1D
patients (T1D-LS). Black symbols: HLA-A2.1–negative subjects; red symbols: HLA-A2.1–positive subjects. Kruskal-Wallis test with
Dunn’s post hoc test (C, D). *P , 0.05, **P , 0.01, ***P , 0.001. G) Responses against both S10010–18 and S10020–28 were more
frequently detected among T1D patients (ND T1D: 57.1%; LS T1D: 60%) compared with HDs (11.1%). Two-tailed Fisher’s exact
test, P = 0.0045. There is also a positive correlation between the responses to both peptides (r = 0.66, Spearman’s correlation, P ,
0.0001). The dashed line (C–G) represents the threshold.
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peptide doses, mice were vaccinated using doses 10 times
lower. Surprisingly, disease kinetics were accelerated,
reaching statistical significancewhen comparedwith both
saline-treated (P = 0.048; log-rank, Mantel-Cox) and non-
manipulated females (Spontaneous. P = 0.02; log-rank,
Mantel-Cox) (Fig. 5A). Vaccination with the NPPEs also
increased the number of highly infiltrated islets (Fig. 5B)
(P = 0.011; Fisher’s exact test).
Similar to the results seen using high doses, IFN-g re-
sponses in mice vaccinated with S10010–18 and S10020–28
[6/13 (46.1%) and 7/13 (53.8%), respectively] are not sig-
nificantly higher compared with those seen in animals
inoculated with saline [S10010–18: 66.7% (8/12); S10020–28:
66.7% (8/12)] or those developing T1D spontaneously
[S10010–18: 61.3% (19/31); S10020–28: 48.4% (15/31)] (Fig.
5C,D) (P. 0.05; Fisher’s exact test).Moreover, vaccination
with S100-b–derivedNPPEsdoes not significantlymodify
the intensity of the response (P = 0.24 for S10010–18 andP =
0.097 for S10020–28; Kruskal-Wallis test). However, the
immunotherapy regime seems to activate the cellular au-
toimmune response against S100-b because a significant
increase in the cytotoxic activity against splenocytes in-
cubated with the peptide epitopes is seen (Fig. 5E) (P ,
0.05 in all effector:target ratios; Mann-Whitney U test),
suggesting that vaccination with S100-b–derived NPPEs
activates an ongoing autoimmune response rather than
triggering a regulatory one.
DISCUSSION
Islet infiltrationbybothCD4+andCD8+T cells is observed
in T1D, but several studies have established an important
role for the latter. In fact, the cytotoxic effector function of
these cells is thought to be one of themechanisms of b-cell
destruction in vivo (38).
During diabetes development, pSC cells, a network of
nervous cells surrounding the islet mass, are also targeted
by the immune system. In NOD mice, as insulitis prog-
resses, pSC cells are gradually eliminated (16–18). pSC
cells express antigens that are either specific, such as
GFAP, or sharedwith theb-cells, such as the neurotrophic
factor S100-b (16). Interestingly, many autoantigens tar-
geted by the immune response in T1D are expressed by
different nervous and neuroendocrine tissues, such as
GAD65, glutamic acid decarboxylase 67, islet cell antigen
512 (also referred to as IA-2), phogrin (also referred to as
IA-2–b), islet cell antigen 69, or chromogranin A (39).
Our group was the first to define NPPEs derived from
S100-b andrestrictedby theHLA-DRB1*04:01 (HLA-DR4)
class IImolecule. T cells frombothNDand long-termT1D
patients recognized the S100-b–derived NPPEs and se-
creted IFN-g (23). In the present study, we defined
S10010–18 and S10020–28 as new HLA-A2.1–restricted epi-
topes. Those epitopeswere recognizedmore frequently by
T cells from both ND and long-term T1D patients. More-
over, the frequency of dual responders (i.e., those
responding to both S100-b peptides) was higher in T1D
patients, particularly long-term ones. Previous studies
have shown that different types of autoimmune responses
could be taking place in T1D patients. Differential insulitic
profiles determine the extent of b-cell destruction and the
age at onset (40); therefore, it remains possible that youn-
ger T1D patients than the ones shown in our study show
more robust S100-b–specific cytotoxic responses, as pre-
viously shown by Banwell et al. for whole antigen in chil-
dren using a proliferation assay (22).
Figure 3. Spontaneous autoimmune responses against S10010-
18 and S10020-28 in A2.1-transgenic NOD mice. A) Spontaneous
autoimmune responses against S10010–18 and S10020–28 were
determined in splenocytes by IFN-g ELISPOT in male (n = 22;
10.32 6 4.76 wk of age, mean 6 SD) and female (n = 31; 9.83 6
3.97, mean 6 SD) A2.1-transgenic NOD mice. Data shown are
the SIs (y axis) calculated as the ratio between the number of
spots with peptide and the number of spots in culture medium
only. SIs $2 were considered positive responses. Median
responses were higher in females compared with males for
S10010–18. B, C) Mann-Whitney U test. P = 0.035. Spontaneous
responses against S10010–18 (B) and S10020–28 (C) according to
age were determined in female mice (n = 31; 5–10 animals/age
group). Positive responses (SI $2) can be detected as early as
5 wk of age for both peptide epitopes. The dashed line
represents the threshold.
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S10010–18 lies in the same region as the HLA-DR4 peptide
epitope S1006–25 (KAMVALIDVFHQYSGREGDK) and
S10020–28 in the regionofS10021–36 (REGDKHKLKKSELKEL).
For otherwell-characterized autoantigens in T1D,MHC class
I– andII–bindingpeptideshavebeenidentifiedinoverlapping
regions or in close proximity (21, 24, 41). Recent data in NOD
mice identified dominant class II–restricted epitopes (S1001-15
and S10078–92) (25) in regions previously identified by us in
humanT1D(23).Thesedatapoint to the fact that thoseregions
are immunodominant in both NOD mice and human T1D
patients and constitute important targets of the autoimmune
response in diabetes.
Proliferative lymphocyte responses against GFAP and
S100-b whole antigens have been detected in both NOD
miceandhumanT1Dpatients (16, 22).TwoGFAP-derived
Kd-restricted epitopes have been identified in the NOD
mice. However, when evaluated for their potential in
preventing diabetes, only the one with the higher MHC
binding affinity was able to significantly delay T1D de-
velopment (21). Our results show that responses against
HLA-A2.1–restricted S100-b NPPEs can be detected as
early as 4 wk of age; however, when used to prevent dis-
ease development, an acceleration was observed, more
aggressive insulitis was detected, no reduction of IFN-g
secretion was seen, and an increase in cytotoxic activity
against S100-b–loaded targets was observed.
Severaldifferencesbetween thepresent studyand those
using other peptide antigens to prevent T1D could explain
the differences. First, GFAP-derived peptide epitopes
were identified using algorithms predicting high binders,
whereas our S100-b–derived peptide epitopes are true
NPPEs with low or no detectable affinity for HLA-A2.1
using an HLA stabilization assay. There is a correlation
between class I binding affinity and immunogenicity of
CTL peptide epitopes (42). It is believed that peptide epi-
topes targeted by CTLs administered systemically in high
doses and in aqueous solutions induce CTL peripheral
tolerance, probably due to the deletion of peptide-specific
CTLs (43, 44). For example, a single subcutaneous vacci-
nation using a peptide derived from the adenovirus type
5 early region 1A oncogene induce a specific CTL
tolerization against adenovirus type 5 early region 1A
oncogene–expressing tumor cells; however, vaccination
with a different peptide (human papillomavirus type 16
E749–57) in similar conditions induces protection in
mice challenged with human papillomavirus type 16–
transformed tumor cells (44). An important difference
between both peptides is their affinity for the restriction
element (H-2Db), with a higher binding affinity showing
for the first peptide. For class II–restricted peptide epi-
topes, peptideswith higherMHCbinding affinity showed
a higher capacity to prevent experimental autoimmune
encephalomyelitis and induce tolerance when adminis-
tered in conditions similar to those shown in the present
study (45).
Second, MHC class I–restricted GFAP peptides (21)
were administered in incomplete Freund’s adjuvant (IFA)
compared with saline in the present study, and this may
contribute to their in vivo stability. In cancer animal
models, peptide/IFA vaccination primed tumor-specific
Figure 4. T1D development in
A2.1-transgenic NOD mice vac-
cinated intraperitoneally with
S10010–18 and S10020–28. A)
Animals were vaccinated with
100 mg each of S10010–18 and
S10020–28 per dose (n = 10;
continuous line) starting at
4 wk of age and then every
2–3 wk until they developed
diabetes or reached 30 wk of
age. Animals inoculated with
saline (n = 12; dotted line) were
used as controls. Vaccination
with S10010–18 and S10020–28
does not seem to significantly
modify either the incidence or
the kinetics of diabetes devel-
opment in A2.1-transgenic
NOD mice. Log-rank, Mantel-
Cox, P = 0.29. B) Insulitis in
A2.1-transgenic NOD mice vac-
cinated with S100-b–derived
NPPEs or inoculated with saline.
The percentage of islets heavily
infiltrated (scores 3 and 4) is
significantly higher in S100-b–
vaccinated animals compared
with those inoculated with saline. Fisher’s exact test; P = 0.0054. C, D) IFN-g secretion in response to S10010–18 (C) and
S10020–28 (D) in A2.1-transgenic NODmice vaccinated with the S100-b–derived NPPEs (S100-b), saline (saline), or nonmanipulated
(spontaneous). In all cases, splenocytes were harvested at disease diagnosis or at 30 wk of age. Neither frequency of positive
responses (Fisher’s exact test, P . 0.05) nor median SI responses (Kruskal-Wallis test, P = 0.4) were significantly different in S100-
b–immunized mice compared with spontaneous and saline-inoculated mice.
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CD8+ T lymphocytes. Those cells accumulated and per-
sisted at the antigen-rich vaccination site, where they be-
came dysfunctional and underwent apoptosis, resulting
in hyporesponsiveness to subsequent peptide boosts.
Vaccination using the same peptides in saline shifted T-
cell location toward tumors, inducing anti-tumor activity
and reducing systemic T-cell dysfunction (46). These data
suggest that antigen clearance promotes CD8+ T-cell
survival and generation of memory T cells, whereas
chronic antigen stimulation leads to tolerance (47). Per-
forming experiments with S100-b–derived NPPEs in IFA
will help to test this hypothesis.
Multiple immunizations using an islet-specific glucose-
6-phosphatase–related protein–derived peptide in saline
protects from diabetes development (30). Repeated trig-
gering of high-avidityCD8+ T cellswith a low-avidity, but
not with a high-affinity, peptide in the periphery before
development of complete insulitis induces tolerance, even
when peptides tested showa high affinity for theKdMHC
molecule. This protection ismediatedby the eliminationof
high-avidity CD8 cells and their substitution by low-
affinity peptide-specific cells. There are no data regarding
the frequency or avidity of S100-b–specific CD8+ T cells in
the A2.1-transgenic NODmice; hence, we speculate that a
combination of low affinity for MHC molecules and a
quick peptide clearance from the injection site leads to the
expansion of high-avidity CD8+ T cells, explaining the
acceleration of T1D in vaccinated animals and the simul-
taneous increase in cytotoxicity against targets pre-
incubated with S100-b NPPEs.
Conflicting results regarding a successful outcome (i.e.,
diabetes prevention) has also been shown for class II–
restricted peptide epitopes recognized by CD4+ T lympho-
cytes. The use of the insulin peptide epitope B9:23
(SHLVEALYLYCGERG) in immunotherapy in the NOD
mice has led to 50% protection (48), no effect (49), or an
increase in disease incidence (50). To explain these discrep-
ancies, it has been proposed that efficient regulatory T cell
induction needs individual peptide optimization and is
greatly influencedby theactivatedstatusof the targetTcells.
Figure 5. T1D diabetes development in A2.1-transgenic NOD mice vaccinated intraperitoneally with low doses of S10010–18 and
S10020–28. A) Animals were vaccinated with 10 mg each of S10010–18 and S10020–28 per dose (n = 10; continuous line) starting at
4 wk of age and then every 2–3 wk until they developed diabetes or reached 30 wk of age. Animals inoculated with saline (n = 12;
black dotted line) were used as controls. Spontaneous disease development in nonmanipulated females (n = 34; gray dotted line)
is also shown. Vaccination with S10010-18 and S10020-28 significantly accelerates the kinetics of diabetes development in A2.1-
transgenic mice compared with both saline-treated (log-rank, Mantel-Cox, P = 0.048) and nonmanipulated (log-rank, Mantel-
Cox, P = 0.02) female mice. B) Insulitis in A2.1-transgenic NOD mice vaccinated with S100-b–derived NPPEs or inoculated with
saline. The percentage of islets heavily infiltrated (scores 3 and 4) is significantly higher in S100-b–vaccinated animals compared
with those inoculated with saline. Fisher’s exact test; P = 0.011. C, D) IFN-g secretion in response to S10010–18 (C) and S10020–28
(D) in A2.1-transgenic NOD mice vaccinated with the S100-b–derived NPPEs (S100-b), saline (saline), or nonmanipulated
(spontaneous). In all cases, splenocytes were harvested at disease diagnosis or at 30 wk of age. Neither frequency of positive
responses (Fisher’s exact test, P . 0.05) nor median SI responses (P = 0.24 for S10010–18 and P = 0.097 for S10020–28; Kruskal-
Wallis test) were significantly different in S100-b–immunized mice compared with spontaneous and saline-inoculated mice. E)
Splenocytes from animals vaccinated with S100-b–derived NNPEs (black line) show a higher specific cytotoxicity against targets
incubated with both S100-b–derived NPPEs compared with that seen in splenocytes from animals inoculated with saline (dotted
line). Mann-Whitney U test, P , 0.05 for all effector:target (E:T) ratios.
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Finally, although both S10010-18 and S10020-28 are
NPPEs eluted from HLA-A2.1 molecules, present results
show that A2.1-negative T1D patients also respond
against these peptide epitopes. These results are not un-
expected since previous results have shown a great ma-
jority of peptide epitopes elicited responses by individuals
not expressing the original restricting HLAmolecule, due
to promiscuous presentation via two or more HLA class I
molecules (51).
In summary, we have identified NPPEs derived from
the calcium-binding S100-b antigen and presented by the
HLA-A*02:01 molecule. Those CTL peptide epitopes are
recognized more frequently by lymphocytes from both
ND and long-term T1D patients compared with HDs.
Similar responses against these NPPEs can be detected in
A2.1-transgenic NOD mice as early as 4 wk of age. Vac-
cination of A2.1-transgenic NOD mice with these NPPEs
seems to accelerate T1D development, increasing insulitis
and triggering the expansion of S100-b–specific CTLs,
probably due to the expansion of high-affinity S100-b–
specific cytotoxic T cells, suggesting that the use of short
HLAclass I–restrictedpeptides to induce toleranceneedsa
careful evaluation of the target cytotoxic population to
avoid its stimulation.
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19. Gómez-Touriño, I., Camiña-Darriba, F., Otero-Romero, I., Rodŕıguez,
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